Agilent Beats Q3, Raises FY26 Outlook on Strong Demand
A sits 43% above its 52-week low of $108.35.
Summary
Agilent delivered a strong Q3: revenue rose 8.1% to $1.88B, beating the $1.84B consensus, and adjusted EPS jumped 18% to $1.62 versus the $1.49 expected. Management raised full-year guidance, now projecting FY26 revenue of $7.49B-$7.51B (up 7.8%-8.1%) and non-GAAP EPS of $6.18-$6.21, up from prior levels. Q4 guidance calls for revenue of $1.98B-$2.0B and EPS of $1.71-$1.74. All segments grew, led by an 11% increase in Life Sciences and Diagnostics Markets Group, and the company cited improving end markets and stronger demand. Q3 margins and EPS also benefited from tariff refunds. The stock trades near its 52-week high, and this beat-and-raise quarter reinforces the positive momentum.
At the time of this announcement, A was trading at $155.40 on NYSE in the Life Sciences sector, with a market capitalization of approximately $43.7B. The 52-week trading range was $108.35 to $160.51. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.